Health research clinic Mayo Clinic has taken part in US-based clinical-stage therapeutics company Seres Health’s $10m in series B financing and will also enter into an exclusive research partnership with the startup.
The round also saw reinvestment from Enso Ventures and Flagship Ventures, both of which participated in Seres’ $10.5m series A round in November 2013.
Seres will use the funding to progress with clinical trials of its medications. Its lead product candidate, SER-109, is currently in clinical testing as a possible drug to help combat recurrent clostridium difficile.
“We are excited about this collaboration because it allows us to deepen our understanding of interactions between the gut microbiome and clinical disease while simultaneously offering the latest treatments for our patients,” said Heidi Nelson, director of the microbiome programme in the Mayo Clinic Center for Individualized Medicine.
“With Seres, we will be able to offer microbiome-based therapies on a trial basis for patients who may not be experiencing relief from traditional treatments.”